HOME >> BIOLOGY >> NEWS
Merck CEO Raymond Gilmartin to lecture at NJIT

Raymond V. Gilmartin, chairman, president and chief executive officer of Merck and Co., Inc., will visit New Jersey Institute of Technology (NJIT) on Feb. 23 to deliver a lecture titled "A Prescription for Change in U.S. Health Care."

As more and more Americans come to rely on prescription drugs to meet their health care needs, the pharmaceutical industry is receiving increasing attention from policy makers at every level. Gilmartin will discuss the ongoing challenges facing the U.S. pharmaceutical industry, with particular focus on the areas of access, affordability, innovation and quality of care.

Merck and Co., Inc. is one of the most respected and successful drug makers in the world. Headquartered in Whitehouse Station, Merck employs nearly 64,000 people worldwide. Merck's global sales were $22.9 billion in 2004.

Since the company was founded in 1891, Merck researchers have pioneered innovations for treating serious diseases a tradition that produced such major medical advances as penicillin, streptomycin and cortisone, among others.

Merck is also well known for its philanthropy. For nearly 20 years, Merck has donated a drug to treat river blindness in Africa and Latin America. The company responded to the recent tsunami disaster by pledging more than $10 million in aid and supplies. Nearer to home, Merck has contributed more than $20 million to the Merck Institute for Science Education, which partners with New Jersey and Pennsylvania school districts to improve science and math education.

Prior to joining Merck in 1994, Gilmartin was chairman, president and chief executive officer of Becton Dickinson. He received a bachelor's degree in electrical engineering from Union College in 1963 and an MBA from Harvard Business School in 1968. He serves on the boards of General Mills, Inc. and the Microsoft Corporation. He is chairman of the Board of Directors of The United Negro College Fund and is a trustee of the Healthcare Le
'"/>

Contact: Robert Florida
florida@njit.edu
973-596-5203
New Jersey Institute of Technology
16-Feb-2005


Page: 1 2

Related biology news :

1. Merck and AAAS announce 2007 winners of Outstanding Undergraduate Research Programs
2. Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration
3. Merck and AAAS announce 2006 winners for Outstanding Undergraduate Research Programs
4. Researchers gain support from Merck Sharp & Dohme for novel area of diabetes research
5. Nobel Laureate Sydney Brenner receives 2005 UCSD/Merck Life Science Achievement Award
6. Merck / AAAS announce 2005 winners for outstanding undergraduate research programs
7. Protein tyrosine phosphatases to be topic of ASBMB-Merck Award lecture
8. Award lectures for ASBMBs 2007 Annual Meeting
9. AACR establishes new lecture in honor of Princess Takamatsu
10. National Academies Advisory: March 5 lecture on ocean acidification
11. Becker to deliver plenary lecture at plasma science meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Merck CEO Raymond Gilmartin lecture NJIT

(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/1/2015)... Mar. 30, 2015 Research and Markets ... of the "Blood Screening Market by Technology ... Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, ... Forecasts to 2019 " report to their ... expected to reach $2.55 billion by 2019 from ...
(Date:4/1/2015)... /CNW/ - Canada,s Research-Based Pharmaceutical Companies ... released report on Cost Drivers of Public Drug Plans in ... the report, the rates of change in drug costs have ... -0.8 percent in 2012/13 for a number of select public ... the costs of medicines without considering their overall impact on ...
(Date:4/1/2015)... Mar. 30, 2015 Research and Markets ... of the "Forensic Technologies and Services - ... offering. This report analyzes the US ... Million by the following Segments: Forensic Databases, Forensic ... Others. Annual estimates and forecasts are ...
(Date:4/1/2015)... 2015 Synthetic Biologics, Inc. (NYSE MKT: ... infections and diseases, with a focus on protecting ... the development of SYN-004, the Company,s candidate therapy ... within the gastrointestinal (GI) tract and maintain the ... prevention of C. difficile infection, antibiotic-associated ...
Breaking Biology Technology:Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 3Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 5Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 6Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 7Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4
Cached News: